提高TAVR指南推荐证据门槛:JACC本周综述
2019年8月16日FDA基于PARTNER 3和Evolut LR两项关键试验批准TAVR用于低危症状性重度主动脉瓣狭窄患者。与中危队列相比,低危试验样本量更小、主要终点事件总数近低3倍,且Evolut LR仅9.8%患者完成2年随访,证据量不足以支持将TAVR作为首选干预。
要点
- 低危TAVR关键试验主要终点事件数显著少于中危队列
- Evolut LR仅9.8%患者完成2年随访,91.2%需模型填补
- 现有证据量不足以推荐TAVR作为低危患者首选干预
核心结论
- 低危主动脉瓣狭窄患者中支持TAVR作为首选干预的证据量不足。
研究设计与样本
- 综述文章,基于PARTNER 3和Evolut Low Risk两项关键试验及FDA批准背景进行证据评述。
主要发现
- 低危试验主要终点事件总数近3倍低于中危队列(193 vs. 615)。
- 低危队列1年全因死亡或致残性卒中总数为62,低于中危、高危和不可手术队列。
- Evolut LR中仅137/1403例(9.8%)完成2年随访,91.2%需基于模型的填补。
临床怎么用
- 对低危症状性重度主动脉瓣狭窄患者,选择TAVR作为首选干预前应审慎评估证据强度。
局限性
- 低危试验样本量较小且主要终点事件数少。
- Evolut LR长期随访数据大量依赖模型填补。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
On August 16, 2019, the U.S. Food and Drug Administration approved expanding the indication for transcatheter aortic valve replacement (TAVR) to low-risk patients with symptomatic severe aortic stenosis. The decision was based on the results of 2 pivotal trials that confirmed superiority (PARTNER [Placement of Aortic Transcatheter Valves] 3) or noninferiority (Evolut Low Risk [LR]) of TAVR as compared with SAVR at 1- and 2-year follow-up, respectively. As compared with intermediate-risk cohorts, the sample size in these trials was smaller and the total number of primary endpoint events was nearly 3 times as low (193 vs. 615). The total number of deaths from any cause or disabling stroke at 1 year in the low-risk cohorts was 62, which is substantially lower than the numbers in intermediate-, high-, and inoperable-risk cohorts. In Evolut LR, only 137 of 1,403 patients (9.8%) completed the 2-year follow-up, with 91.2% requiring model-based imputation. Thus, the quantum of evidence is insufficient for endorsing TAVR as the preferred intervention for these patients.
引用
- Kaul S. Raising the Evidentiary Bar for Guideline Recommendations for TAVR: JACC Review Topic of the Week. J Am Coll Cardiol. 2020. PMID: 32819472. doi:10.1016/j.jacc.2020.05.085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。